Can you take Busulfan with Stimufend?

Busulfan has a major potential interaction with Bleeding Disorder.

Busulfan induces severe and prolonged myelosuppression at the recommended dosage. Hematopoietic progenitor cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression. It is recommended to closely monitor complete blood counts, including white blood cell differentials, and quantitative platelet counts daily during treatment and until engraftment is demonstrated. Extreme caution should be exercised if busulfan is administered in patients whose bone marrow reserve may be compromised by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression, such as fever, sore throat, local infection, bleeding, or symptoms of anemia.

Busulfan has a major potential interaction with Bone Marrow Depression/Low Blood Counts.

Busulfan induces severe and prolonged myelosuppression at the recommended dosage. Hematopoietic progenitor cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression. It is recommended to closely monitor complete blood counts, including white blood cell differentials, and quantitative platelet counts daily during treatment and until engraftment is demonstrated. Extreme caution should be exercised if busulfan is administered in patients whose bone marrow reserve may be compromised by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression, such as fever, sore throat, local infection, bleeding, or symptoms of anemia.

Busulfan has a major potential interaction with Fever.

Busulfan induces severe and prolonged myelosuppression at the recommended dosage. Hematopoietic progenitor cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression. It is recommended to closely monitor complete blood counts, including white blood cell differentials, and quantitative platelet counts daily during treatment and until engraftment is demonstrated. Extreme caution should be exercised if busulfan is administered in patients whose bone marrow reserve may be compromised by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression, such as fever, sore throat, local infection, bleeding, or symptoms of anemia.

Busulfan has a moderate potential interaction with Head Injury.

Seizures have been reported in patients receiving high doses of busulfan. Therapy with busulfan should be administered cautiously to patients with a history of a seizure disorder or head trauma or who are receiving other potentially epileptogenic drugs.

Busulfan has a major potential interaction with Infection.

Busulfan can induce severe and prolonged myelosuppression. Treatment with busulfan should not be initiated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with busulfan. Close clinical monitoring of hematopoietic function is recommended.

The pegfilgrastim in Stimufend has a major potential interaction with Leukocytosis.

Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells. Therefore, these should not be used in patients with leukocytosis. If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.

The pegfilgrastim in Stimufend has a major potential interaction with Myeloproliferative Disorders.

Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies. Therapy with these drugs should be administered cautiously in patients with myeloid tumors. Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product. The effect of reinfusion of tumor cells is uncertain at this time.

The pegfilgrastim in Stimufend has a major potential interaction with Renal Dysfunction.

Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis. Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production. Advise patients to report signs or symptoms of glomerulonephritis immediately. Monitoring of patients with renal dysfunction is recommended.

Busulfan has a moderate potential interaction with Seizures.

Seizures have been reported in patients receiving high doses of busulfan. Therapy with busulfan should be administered cautiously to patients with a history of a seizure disorder or head trauma or who are receiving other potentially epileptogenic drugs.

Busulfan has a moderate potential interaction with Thalassemia.

Cardiac tamponade during high dose busulfan therapy combined with cyclophosphamide has been reported in pediatric patients with thalassemia. Abdominal pain and vomiting may precede the tamponade. Cardiac tamponade can result in death and therapy with busulfan should be administered cautiously to patients with thalassemia.